84337-86-0

Basic information

• Product Name: 4'-BroMo[1,1'-biphenyl]-4-Methanol,4-(4-broMophenyl)phenyl-Methanol
• Synonyms: 4'-BroMo[1,1'-biphenyl]-4-Methanol,4-(4-broMophenyl)phenyl-Methanol
• CAS NO: 84337-86-0
• Molecular Formula: C₁₃H₁₁BrO
• Molecular Weight: 263.12984
• Mol File: 84337-86-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4'-BroMo[1,1'-biphenyl]-4-Methanol,4-(4-broMophenyl)phenyl-Methanol(CAS DataBase Reference)
• NIST Chemistry Reference: 4'-BroMo[1,1'-biphenyl]-4-Methanol,4-(4-broMophenyl)phenyl-Methanol(84337-86-0)
• EPA Substance Registry System: 4'-BroMo[1,1'-biphenyl]-4-Methanol,4-(4-broMophenyl)phenyl-Methanol(84337-86-0)

Safety Data

• Hazardous Substances Data: 84337-86-0(Hazardous Substances Data)

Upstream product

• 59016-93-2 p-hydroxymethylphenylboronic acid 
• 177490-72-1 (4-Bromo-phenyl)-chloromethoxymethyl-dimethyl-silane 
• 17902-37-3 1-bromo-4-[(chloromethyl)dimethylsilyl]benzene 
• 5467-74-3 4-Bromophenylboronic acid 
• 619-44-3 methyl 4-iodobenzoate 
• 589-87-7 1,4-bromoiodobenzene 
• 89901-03-1 methyl 4’-bromo-[1,1’-diphenyl]-4-carboxylate 
• 50670-57-0 4-bromo-4'-(bromomethyl)-1,1'-biphenyl 
• 50670-49-0 4-bromo-4'-methylbiphenyl 
• 177490-80-1 Acetic acid [(4-bromo-phenyl)-dimethyl-silanyl]-methyl ester 
• 177490-81-2 [(4-Bromo-phenyl)-dimethyl-silanyl]-methanol 
• 106-37-6 1.4-dibromobenzene 
• 92-86-4 4-(4-bromophenyl)bromobenzene 
• 50670-58-1 4-formyl-4'-bromobiphenyl 

Downstream Products

• 1296273-68-1 ethyl ({[5-hydroxy-2-({1-[4'-(hydroxymethyl)biphenyl-4-yl]piperidin-4-yl}methyl)-6-methylpyrimidin-4-yl]carbonyl}amino)acetate 
• 1296274-40-2 ethyl ({[5-(benzyloxy)-2-({1-[4'-(hydroxymethyl)biphenyl-4-yl]piperidin-4-yl}methyl)-6-methylpyrimidin-4-yl]carbonyl}amino)acetate-d1 
• 1296274-39-9 ethyl ({[5-(benzyloxy)-2-{[1-(4'-formylbiphenyl-4-yl)piperidin-4-yl]methyl}-6-methylpyrimidin-4-yl]carbonyl}amino)acetate 
• 1296274-29-7 benzyl ({[5-hydroxy-2-({1-[4'-(hydroxymethyl)biphenyl-4-yl]piperidin-4-yl}methyl)-6-methylpyrimidin-4-yl]carbonyl}amino)acetate 
• 1296274-30-0 4-{[2-(benzyloxy)-2-oxoethyl]carbamoyl}-2-{[1-(4'-{[(2,2-dimethylpropanoyl)oxy]methyl}biphenyl-4-yl)piperidin-4-yl]methyl}-6-methylpyrimidin-5-yl pivalate 
• 1296273-66-9 ethyl ({[5-(benzyloxy)-2-({1-[4'-(hydroxymethyl)biphenyl-4-yl]piperidin-4-yl}methyl)-6-methylpyrimidin-4-yl]carbonyl}amino)acetate 
• 1296273-67-0 5-(benzyloxy)-2-{(1-[4'-(hydroxymethyl)biphenyl-4-yl]piperidin-4-yl}methyl)-6-methylpyrimidine-4-carboxylic acid 
• 1296273-65-8 tert-butyl 5-(benzyloxy)-2-{(1-[4'-(hydroxymethyl)biphenyl-4-yl]piperidin-4-yl}methyl)-6-methylpyrimidine-4-carboxylate 
• 1296273-64-7 tert-butyl 5-(benzyloxy)-2-{(1-[4'-({[tert-butyl(dimethyl)silyl]oxy}methyl)biphenyl-4-yl]piperidin-4-yl}methyl)-6-methylpyrimidine-4-carboxylate 
• 1296273-08-9 ({[2-{(1-[4'-(acetoxymethyl)biphenyl-4-yl]piperidin-4-yl}methyl)-5-hydroxy-6-methylpyrimidin-4-yl]carbonyl}amino)acetic acid 
• 1296273-07-8 ({[5-hydroxy-2-({1-[4’-(hydroxymethyl)biphenyl-4-yl]piperidin-4-yl}methyl)-6-methylpyrimidin-4-yl]carbonyl}amino)acetic acid 
• 1006378-59-1 (4'-(hydroxymethyl)biphenyl-4-yl)triphenylphosphonium bromide 
• 50670-57-0 4-bromo-4'-(bromomethyl)-1,1'-biphenyl 

Relevant articles and documents

Functionalised phosphonate ester supported lanthanide (Ln = La, Nd, Dy, Er) complexes

A series of phosphonate ester supported lanthanide complexes bearing functionalities for subsequent immobilisation on semiconductor surfaces are prepared. Six phosphonate ester ligands (L1-L6) with varying aromatic residues are synthesised. Subsequent com

Dendrimer and organic light-emitting device using the same

A dendrimer and an organic light-emitting device including an organic layer having the dendrimer.

PHENYL SUBSTITUTED CARBOXYLIC ACIDS

Disclosed are compounds and pharmaceutically acceptable salts of formula (A): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

SUBSTITUTED AMINO CARBOXYLIC ACIDS

Disclosed are compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

PHENYL SUBSTITUTED CARBOXYLIC ACIDS

Disclosed are compounds and pharmaceutically acceptable salts of formula (A): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

N-(4-biphenylmethyl)imidazoles as potential therapeutics for the treatment of prostate cancer: Metabolic robustness due to fluorine substitution?

3,3′,5,5′- And 2,2′,6,6′-tetrafluoro-substituted 1-[(1,1′-biphenyl]-4-yl)methyl]-1H-imidazoles were synthesized as inhibitors of 17α-hydroxylase-C17,20-lyase (P450 17, CYP 17). P450 17 is the key enzyme of androgen biosynthesis. Its inhibition is a novel

Silicon directed ipso-substitution of polymer bound arylsilanes: Preparation of biaryls via the Suzuki cross-coupling reaction

A method for attaching haloarylsilanes to polymer support was developed. The polymer bound arylhalide were reacted with a variety of ArB(OH)2 under the Suzuki cross-coupling reaction conditions and the coupled resins were cleaved by different electrophiles to give ipso-substitution products in good yields.

Conformationally Restricted Retinoids

A series of conformationally restricted retinoids was synthesized and screened in two assays used to measure the ability of retinoids to control cell differentiation, namely, the reversal of keratinization in tracheal organ culture from vitamin A deficient hamsters and the inhibition of the induction of mouse epidermal ornithine decarboxylase by a tumor promoter.These compounds had bonds corresponding to selected bonds of the E-tetraene chain of retinoic acid (1) held in a planar cisoid conformation by inclusion in an aromatic ring.The meta-substituted analogue 3 of 4-benzoic acid (2) was far less active than 2 in both assays.In contrast, the vinyl homologue of 2 (4) and the 7,8-dihydro and 7,8-methano analogues (5 and 6) had activity comparable to that of 2.Analogues of 4-benzoic acid (7) were also screened.Replacement of the tetrahydronaphthalene ring of 7 by a benzonorbornenyl group (9) significantly reduced activity, as did removal of the vinylic methyl group from 9 (10).Replacement of the propenyl group of 9 by a cyclopropane ring (12) also reduced activity.Replacement of the tetrahydronaphthalene ring of 7 by 4,4-dimethyl-3,4-dihydro-2H-1-benzopyran and -benzothiopyran rings (13 and 14) also decreased activity.Inclusion of the 7,9 double bond system of 1 in an aromatic ring (15 and 16) reduced activity, whereas inclusion of the 5,7 double bond system in an aromatic ring enhanced activity (7 and 19).Inclusion of the 11,13 and 9,11,13 double bond systems in aromatic rings (2 and 18) also reduced activity below that of 1.Retinoic acid, 7, 13, 14, and 19 inhibited papilloma tumor formation in mice.Toxicity testing indicated that 7 was more toxic than 1, 13, 14, and 19, 19 was more toxic than 1, and 13 and 14 were less toxic than 1.